Bellerophon Therapeutics, Inc.
Compare this stock
BLPH Stock Report Card
$
33%
Performance
Score:
10/100
BLPH returned -90.60% in the last 12 months. Based on SPY's performance of -11.83%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
Score:
75/100
1 analysts offer 12-month price targets for BLPH. Together, they have an average target of 19, the most optimistic target put BLPH at 19 within 12-months and the most pessimistic has BLPH at 19. These analyst ratings are from our partners at Financial Modeling Prep (https://site.financialmodelingprep.com/) and Alpha Vantage (https://www.alphavantage.co/).
Technicals
Score:
11/100
BLPH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
Score:
36/100
BLPH has missed earnings 3 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, BLPH has had 2 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
Score:
57/100
BLPH has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.
Bellerophon Therapeutics, Inc. Summary
Nasdaq / BLPH
Healthcare
Biotechnology
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
BLPH scored poorly on our reportcard. Here are some similar companies and how they performed.
